<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01313637</url>
  </required_header>
  <id_info>
    <org_study_id>113361</org_study_id>
    <secondary_id>2010-023348-33</secondary_id>
    <nct_id>NCT01313637</nct_id>
  </id_info>
  <brief_title>A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD</brief_title>
  <acronym>DB2113361</acronym>
  <official_title>A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group
      study to evaluate the efficacy and safety of GSK573719/GW642444 Inhalation Powder, GSK573719
      Inhalation Powder, GW642444 Inhalation Powder and Placebo when administered once-daily via a
      Novel Dry Powder Inhaler over a 24-week treatment period in subjects with COPD. Subjects who
      meet eligibility criteria at Screening (Visit 1) will complete a 7 to14 day run-in period
      followed by a randomization visit (Visit 2) then a 24-week treatment period. There will be a
      total of 9 clinic study visits. A follow-up phone contact for adverse event assessment will
      be conducted approximately one week after the last study visit (Visit 9 or Early Withdrawal).
      The total duration of subject participation in the study will be approximately 27 weeks. A
      subset of subjects at selected sites will also perform 24-hour serial spirometry and Holter
      monitoring during the study and provide serial blood samples for pharmacokinetic analysis.
      Sparse pharmacokinetic sampling for population pharmacokinetic analyses will be obtained from
      non-subset subjects. The primary measure of efficacy is clinic visit trough
      (pre-bronchodilator and pre-dose) FEV1 on Treatment Day 169. Safety will be assessed by
      adverse events, 12-lead ECGs, vital signs, clinical laboratory tests, and 24 hour Holter
      monitoring (subset only).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 24-week, phase III multicenter, randomized, double-blind, placebo-controlled,
      parallel-group study.

      Eligible subjects will be randomized to GSK573719/GW642444 125/25mcg, GSK573719 125mcg,
      GW642444 25mcg, and placebo treatment groups in a 3:3:3:2 ratio such that of the planned 1463
      total number of randomized subjects approximately 399 subjects will be randomized to each
      active treatment group and 266 subjects will be randomized to placebo. All treatments will be
      administered once-daily in the morning by inhalation using a Novel Dry Powder Inhaler (Novel
      DPI).

      There will be a total of 9 study clinic visits conducted on an outpatient basis. Subjects who
      meet the eligibility criteria at Screening (Visit 1) will complete a 7 to 14 day run-in
      period followed by a 24-week treatment period. Clinic visits will be at Screening,
      Randomization (Day 1), Day 2, after 4, 8, 12, 16, and 24-weeks of treatment, and 1 day after
      the Week 24 Visit (also referred as Treatment Day 169). A follow-up contact for adverse
      assessment will be conducted by telephone approximately 7 days after Visit 9 or the Early
      Withdrawal Visit. The total duration of subject participation, including follow-up will be
      approximately 27 weeks. All subjects will be provided with albuterol/salbutamol for use on an
      &quot;as-needed&quot; basis throughout the run-in and study treatment periods.

      At screening, pre-bronchodilator spirometry testing will be followed by
      post-albuterol/salbutamol spirometry testing. Post-albuterol/salbutamol FEV1 and FEV1/FVC
      values will be used to determine subject eligibility. To further characterize bronchodilator
      responsiveness, post-ipratropium testing will be conducted following completion of
      post-albuterol/salbutamol spirometry.

      Spirometry will be conducted at each post-randomization clinic visit. Six hour post-dose
      serial spirometry will be conducted at Visits 2, 4, 6, and 8. Trough spirometry will be
      obtained 23 and 24 hours after the previous day's dose of blinded study medication at Visits
      3 to 9. All subjects will be provided with an electronic diary (eDiary) for completion daily
      in the evening throughout the run-in and treatment periods. Subjects will use the eDiary to
      record dyspnea scores using the Shortness of Breath with Daily Activities instrument (SOBDA),
      daily use of supplemental albuterol/salbutamol as either puffs/day from a metered-dose
      inhaler (MDI) and/or nebules used per day, and any healthcare contacts related to COPD.

      Additional assessments of dyspnea will be obtained using the Baseline and Transition Dyspnea
      Index (BDI/TDI) which is an interviewer based instrument. At Visit 2, the severity of dyspnea
      at baseline will be assessed using the BDI. At subsequent visits (Visits 4, 6, and 8) change
      from baseline will be assessed using the TDI. Disease specific health status will be
      evaluated using the subject-completed St. George's Respiratory Questionnaire (SGRQ). The SGRQ
      will be completed at Visits 2, 4, 6, and 8. Administration of the SGRQ and BDI/TDI should be
      done prior to spirometry testing.

      The occurrence of adverse events will be evaluated throughout the study beginning at Visit 2.
      SAEs will be collected over the same time period as for AEs. However, any SAEs assessed as
      related to study participation (e.g., study treatment, protocol-mandated procedures, invasive
      tests, or change in existing therapy) or related to a GSK concomitant medication, will be
      recorded from the time a subject consents to participate in the study up to and including any
      follow up contact.

      Additional safety assessments of vital signs (blood pressure and pulse rate), 12-lead ECGs
      and standard clinical laboratory tests (hematology and chemistry) will be obtained at
      selected clinic visits. Blood samples for population pharmacokinetic analyses will be
      obtained.

      At selected study sites, a subset of approximately 198 subjects will perform 24-hour serial
      spirometry during the study for evaluation of lung function over the dosing period. In
      conjunction with the serial spirometry, this subset of subjects will also perform 24 hour
      Holter monitoring and provide blood samples for PK analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1, 2011</start_date>
  <completion_date type="Actual">April 19, 2012</completion_date>
  <primary_completion_date type="Actual">March 1, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)</measure>
    <time_frame>Baseline and Day 169</time_frame>
    <description>FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 28, 56, 84, 112, 168, and 169. Baseline is defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24 hours after the previous morning's dosing (ie., trough FEV1 on Day 169 is the mean of the FEV1 values obtained 23 and 24 hours after the morning dosing on Day 168). Change from Baseline at a particular visit was calculated as the trough FEV1 at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline , smoking status, center group, day, and day by Baseline and day by treatment interactions. ITT=Intent-to-Treat; par.=participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Transition Dyspnea Index (TDI) Focal Score at Day 168 (Week 24)</measure>
    <time_frame>Day 168 (Week 24)</time_frame>
    <description>Considered an 'other' endpoint by the FDA. The TDI is an interviewer-administered instrument which measures the changes in the participant's dyspnea from Baseline. This questionnaire was collected on Days 28, 84 and 168. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9. Analysis was performed using a repeated measures model with covariates of treatment, Baseline dyspnea index (BDI) focal score,smoking status, center group, day, day by BDI focal score and day by treatment interactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168</measure>
    <time_frame>Baseline and Day 168</time_frame>
    <description>FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The WM FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The WM was calculated at Days 1, 28, 84, and 168 using the 0-6-hour post-dose FEV1 measurements collected on that day, which included pre-dose (Day 1: 30 minutes [min] and 5 min prior to dosing; other serial visits: 23 and 24 hours after the previous morning dose) and post-dose at 15 min, 30 min, 1 hour, 3 hours, and 6 hours. Change from Baseline at a particular visit was calculated as the WM at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made 30 min and 5 min pre-dose on Day 1), smoking status, center group, day, and day by Baseline and day by treatment interactions.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline in the Mean Shortness of Breath With Daily Activities (SOBDA) Score for Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The newly developed SOBDA questionnaire assesses dyspnea or shortness of breath (SOB) with daily activities. The SOBDA questionnaire is made up of 13 items completed by the participant (par.) each evening prior to bedtime, when the par. is instructed to reflect on the current day's activities. The daily score is computed as the mean of the scores on the 13 items (&gt;=7 items must have non-missing responses for this to be calculated). The par. is assigned a weekly mean SOBDA score ranging from 1 to 4 (greater scores indicate more severe breathlessness with daily activities) based on the mean of 7 days of data (&gt;=4 of 7 days must be completed for a weekly mean to be calculated). Change from BL is the mean weekly SOBDA score minus BL. Analysis was performed using MMRM with covariates of treatment, BL (mean score in the week prior to treatment), smoking status, center group, week, week by BL and week by treatment interactions. This MMRM analysis only included Weeks 4, 8, 12, and 24.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1493</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>GSK573719/GW642444</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>125/25mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK573719</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>125mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GW642444</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK573719/GW642444 125/25mcg</intervention_name>
    <description>125/25mcg</description>
    <arm_group_label>GSK573719/GW642444</arm_group_label>
    <other_name>umeclidinium bromide/vilanterol trifenatate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK573719 125mcg</intervention_name>
    <description>125mcg</description>
    <arm_group_label>GSK573719</arm_group_label>
    <other_name>umeclidinium bromide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW642444 25mcg</intervention_name>
    <description>25mcg</description>
    <arm_group_label>GW642444</arm_group_label>
    <other_name>vilanterol trifenatate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo only</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of COPD

          -  10 pack-year or greater history of cigarette smoking

          -  Post-bronchodilator FEV1/FVC of &lt;0.7

          -  Predicted FEV1 of 70% of normal or less

          -  Modified Medical Research Council (mMRC) dyspnea score of 2 or greater

        Exclusion Criteria:

          -  Women who are pregnant, lactating, or planning to become pregnant

          -  Respiratory disorders other than COPD, including a current diagnosis of asthma

          -  Clinically significant non-respiratory diseases or abnormalities that are not
             adequately controlled

          -  Significant allergy or hypersensitivity to anticholinergics, beta2-agonists, or the
             excipients of magnesium stereate or lactose used in the inhaler delivery device

          -  Hospitalization for COPD or pneumonia within 12 weeks prior to screening

          -  Lung volume reduction surgery within 12 weeks prior to screening

          -  Abnormal and clinically significant ECG findings at screening

          -  Clinically significant laboratory findings at screening

          -  Use of systemic corticosteroids, antibiotics for respiratory tract infections, strong
             cytochrome P450 3A4 inhibitors, high dose inhaled steroids (&gt;1000mcg fluticasone
             propionate or equivalent), PDE4 inhibitors, tiotropium, oral beta2-agoinists, short-
             and long-acting inhaled beta2-agonists, ipratropium, inhaled sodium cromoglycate or
             nedocromil sodium, or investigational medicines for defined time periods prior to the
             screening visit

          -  Use of long-term oxygen therapy (12 hours or greater per day)

          -  Regular use of nebulized treatment with short-acting bronchodilators

          -  Participation in the acute phase of a pulmonary rehabilitation program

          -  A know or suspected history of alcohol or drug abuse

          -  Affiliation with the investigational site

          -  Previous use of GSK573719 or GW642444 alone or in combination, including the
             combination of fluticasone furoate and GW642444
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <zip>35501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <zip>29379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>København</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Naestved</city>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roedovre</city>
        <zip>2610</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haapsalu</city>
        <zip>90502</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Parnu</city>
        <zip>80010</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rakvere</city>
        <zip>44316</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10117</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lyon cedex 04</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montauban cedex</city>
        <zip>82017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Reims Cedex</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tarbes Cedex 09</city>
        <zip>65013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toulon</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tours cedex 9</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vieux Condé</city>
        <zip>59690</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dillingen</city>
        <state>Bayern</state>
        <zip>89407</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kuenzing</city>
        <state>Bayern</state>
        <zip>94550</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80809</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schwabach</city>
        <state>Bayern</state>
        <zip>91126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gelnhausen</city>
        <state>Hessen</state>
        <zip>63571</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Neu-Isenburg</city>
        <state>Hessen</state>
        <zip>63263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rodgau</city>
        <state>Hessen</state>
        <zip>63110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzg</city>
        <state>Sachsen</state>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Geesthacht</city>
        <state>Schleswig-Holstein</state>
        <zip>21502</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schmoelln</city>
        <state>Thueringen</state>
        <zip>04626</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13581</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Balassagyarmat</city>
        <zip>2660</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Deszk</city>
        <zip>6772</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Farkasgyepű</city>
        <zip>8582</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gyöngyös</city>
        <zip>3200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gödöllő</city>
        <zip>2100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Szikszó</city>
        <zip>3800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sátoraljaújhely</city>
        <zip>3980</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Törökbálint</city>
        <zip>2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aichi</city>
        <zip>454-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aichi</city>
        <zip>455-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aichi</city>
        <zip>457-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chiba</city>
        <zip>296-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>802-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-3195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>832-0059</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>070-8644</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ibaraki</city>
        <zip>319-1113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>252-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miyagi</city>
        <zip>989-1253</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okayama</city>
        <zip>714-0081</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>596-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shizuoka</city>
        <zip>434-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>171-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>194-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>204-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Almelo</city>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Almere</city>
        <zip>1311 RL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beek</city>
        <zip>6191 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>EDE</city>
        <zip>6716 RP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Enschede</city>
        <zip>7513 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helmond</city>
        <zip>5707 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hoorn</city>
        <zip>1624 NP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tubbergen</city>
        <zip>7651 JH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Veldhoven</city>
        <zip>5504 DB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zutphen</city>
        <zip>7207 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bekkestua</city>
        <zip>1319</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bergen</city>
        <zip>5017</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bodø</city>
        <zip>8005</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elverum</city>
        <zip>2408</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kløfta</city>
        <zip>2040</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Skedsmokorset</city>
        <zip>N-2020</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stavanger</city>
        <zip>4005</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trondheim</city>
        <zip>7011</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trondheim</city>
        <zip>7027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dasmariñas, Cavite</city>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marikina City</city>
        <zip>1800</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marilao, Bulacan</city>
        <zip>3019</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1109</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bardejov</city>
        <zip>085 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Humenne</city>
        <zip>066 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poprad</city>
        <zip>058 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Revuca</city>
        <zip>050 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spisska Nova Ves</city>
        <zip>052 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vrable</city>
        <zip>952 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-412 63</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Höllviken</city>
        <zip>SE-236 32</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Linköping</city>
        <zip>SE-582 16</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Luleå</city>
        <zip>SE-971 89</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malmö</city>
        <zip>SE-211 52</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-111 57</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-113 61</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vällingby</city>
        <zip>SE-162 68</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Donetsk</city>
        <zip>83099</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61124</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kiev</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Simferopol</city>
        <zip>95043</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zaporizhia</city>
        <zip>69035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>Slovakia</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2011</study_first_submitted>
  <study_first_submitted_qc>March 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2011</study_first_posted>
  <results_first_submitted>December 19, 2013</results_first_submitted>
  <results_first_submitted_qc>December 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 10, 2014</results_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anticholinergic</keyword>
  <keyword>long-acting beta agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_id>113361</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113361</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113361</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113361</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113361</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113361</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113361</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants (par.) who met eligibility criteria at Screening (Visit 1) completed a 7- to14-day run-in period and were then randomized to a 24-week treatment (trt.) period. A total of 2114 participants were screened; 1493 participants were randomized, and 1489 participants took at least one dose of randomized medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received matching placebo once daily (QD) via a dry powder inhaler (DPI) in the morning for 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>UMEC 125 µg QD</title>
          <description>Participants received umeclidinium bromide (UMEC) 125 micrograms (µg) QD via a DPI in the morning for 24 weeks.</description>
        </group>
        <group group_id="P3">
          <title>VI 25 µg QD</title>
          <description>Participants received vilanterol (VI) 25 µg QD via a DPI for 24 weeks.</description>
        </group>
        <group group_id="P4">
          <title>UMEC/VI 125/25 µg QD</title>
          <description>Participants received UMEC/VI 125/25 µg QD via a DPI in the morning for 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="275"/>
                <participants group_id="P2" count="407"/>
                <participants group_id="P3" count="404"/>
                <participants group_id="P4" count="403"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="312"/>
                <participants group_id="P3" count="298"/>
                <participants group_id="P4" count="325"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="106"/>
                <participants group_id="P4" count="78"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met Protocol- Defined Stopping Criteria</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received matching placebo once daily (QD) via a dry powder inhaler (DPI) in the morning for 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>UMEC 125 µg</title>
          <description>Participants received UMEC 125 µg QD via a DPI in the morning for 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>VI 25 µg</title>
          <description>Participants received VI 25 µg QD via a DPI for 24 weeks.</description>
        </group>
        <group group_id="B4">
          <title>UMEC/VI 125/25 µg</title>
          <description>Participants received UMEC/VI 125/25 µg QD via a DPI in the morning for 24 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="275"/>
            <count group_id="B2" value="407"/>
            <count group_id="B3" value="404"/>
            <count group_id="B4" value="403"/>
            <count group_id="B5" value="1489"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" spread="8.53"/>
                    <measurement group_id="B2" value="63.1" spread="8.48"/>
                    <measurement group_id="B3" value="62.8" spread="8.80"/>
                    <measurement group_id="B4" value="63.4" spread="8.08"/>
                    <measurement group_id="B5" value="62.9" spread="8.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="139"/>
                    <measurement group_id="B4" value="139"/>
                    <measurement group_id="B5" value="515"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                    <measurement group_id="B2" value="270"/>
                    <measurement group_id="B3" value="265"/>
                    <measurement group_id="B4" value="264"/>
                    <measurement group_id="B5" value="974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American/African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Central/South Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Japanese Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - South East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - Arabic/North African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="237"/>
                    <measurement group_id="B2" value="361"/>
                    <measurement group_id="B3" value="353"/>
                    <measurement group_id="B4" value="359"/>
                    <measurement group_id="B5" value="1310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)</title>
        <description>FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 28, 56, 84, 112, 168, and 169. Baseline is defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24 hours after the previous morning's dosing (ie., trough FEV1 on Day 169 is the mean of the FEV1 values obtained 23 and 24 hours after the morning dosing on Day 168). Change from Baseline at a particular visit was calculated as the trough FEV1 at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline , smoking status, center group, day, and day by Baseline and day by treatment interactions. ITT=Intent-to-Treat; par.=participants.</description>
        <time_frame>Baseline and Day 169</time_frame>
        <population>Intent-to-Treat (ITT) Population: all par. randomized to trt. who received at least one dose of randomized study drug. Par. represents those with data available at the time point being presented; however, all par. in the ITT population without missing covariate information and with at least one post BL measurement are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo QD via a DPI in the morning for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>UMEC 125 µg</title>
            <description>Participants received UMEC 125 µg QD via a DPI in the morning for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>VI 25 µg</title>
            <description>Participants received VI 25 µg QD via a DPI for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>UMEC/VI 125/25 µg</title>
            <description>Participants received UMEC/VI 125/25 µg QD via a DPI in the morning for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)</title>
          <description>FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 28, 56, 84, 112, 168, and 169. Baseline is defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24 hours after the previous morning's dosing (ie., trough FEV1 on Day 169 is the mean of the FEV1 values obtained 23 and 24 hours after the morning dosing on Day 168). Change from Baseline at a particular visit was calculated as the trough FEV1 at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline , smoking status, center group, day, and day by Baseline and day by treatment interactions. ITT=Intent-to-Treat; par.=participants.</description>
          <population>Intent-to-Treat (ITT) Population: all par. randomized to trt. who received at least one dose of randomized study drug. Par. represents those with data available at the time point being presented; however, all par. in the ITT population without missing covariate information and with at least one post BL measurement are included in the analysis.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="312"/>
                <count group_id="O3" value="299"/>
                <count group_id="O4" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.031" spread="0.0153"/>
                    <measurement group_id="O2" value="0.129" spread="0.0119"/>
                    <measurement group_id="O3" value="0.093" spread="0.0121"/>
                    <measurement group_id="O4" value="0.207" spread="0.0119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.160</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.122</ci_lower_limit>
            <ci_upper_limit>0.198</ci_upper_limit>
            <estimate_desc>Least squares mean difference=UMEC 125 µg minus Placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.124</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.086</ci_lower_limit>
            <ci_upper_limit>0.162</ci_upper_limit>
            <estimate_desc>Least squares mean difference=VI 25 µg minus Placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.238</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.200</ci_lower_limit>
            <ci_upper_limit>0.276</ci_upper_limit>
            <estimate_desc>Least squares mean difference=UMEC/VI 125/25 µg minus Placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.079</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.046</ci_lower_limit>
            <ci_upper_limit>0.112</ci_upper_limit>
            <estimate_desc>Least squares mean difference=UMEC/VI 125/25 minus UMEC 125 µg.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.114</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.081</ci_lower_limit>
            <ci_upper_limit>0.148</ci_upper_limit>
            <estimate_desc>Least squares mean difference=UMEC/VI 125/25 minus VI 25 µg.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Transition Dyspnea Index (TDI) Focal Score at Day 168 (Week 24)</title>
        <description>Considered an 'other' endpoint by the FDA. The TDI is an interviewer-administered instrument which measures the changes in the participant's dyspnea from Baseline. This questionnaire was collected on Days 28, 84 and 168. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9. Analysis was performed using a repeated measures model with covariates of treatment, Baseline dyspnea index (BDI) focal score,smoking status, center group, day, day by BDI focal score and day by treatment interactions.</description>
        <time_frame>Day 168 (Week 24)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all par. randomized to trt. who received at least one dose of randomized study drug. Par. represents those with data available at the time point being presented; however, all par. in the ITT population without missing covariate information and with at least one post BL measurement are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo QD via a DPI in the morning for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>UMEC 125 µg</title>
            <description>Participants received UMEC 125 µg QD via a DPI in the morning for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>VI 25 µg</title>
            <description>Participants received VI 25 µg QD via a DPI for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>UMEC/VI 125/25 µg</title>
            <description>Participants received UMEC/VI 125/25 µg QD via a DPI in the morning for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Transition Dyspnea Index (TDI) Focal Score at Day 168 (Week 24)</title>
          <description>Considered an 'other' endpoint by the FDA. The TDI is an interviewer-administered instrument which measures the changes in the participant's dyspnea from Baseline. This questionnaire was collected on Days 28, 84 and 168. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9. Analysis was performed using a repeated measures model with covariates of treatment, Baseline dyspnea index (BDI) focal score,smoking status, center group, day, day by BDI focal score and day by treatment interactions.</description>
          <population>Intent-to-Treat (ITT) Population: all par. randomized to trt. who received at least one dose of randomized study drug. Par. represents those with data available at the time point being presented; however, all par. in the ITT population without missing covariate information and with at least one post BL measurement are included in the analysis.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="313"/>
                <count group_id="O3" value="294"/>
                <count group_id="O4" value="324"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.20"/>
                    <measurement group_id="O2" value="1.2" spread="0.16"/>
                    <measurement group_id="O3" value="1.3" spread="0.16"/>
                    <measurement group_id="O4" value="1.8" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168</title>
        <description>FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The WM FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The WM was calculated at Days 1, 28, 84, and 168 using the 0-6-hour post-dose FEV1 measurements collected on that day, which included pre-dose (Day 1: 30 minutes [min] and 5 min prior to dosing; other serial visits: 23 and 24 hours after the previous morning dose) and post-dose at 15 min, 30 min, 1 hour, 3 hours, and 6 hours. Change from Baseline at a particular visit was calculated as the WM at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made 30 min and 5 min pre-dose on Day 1), smoking status, center group, day, and day by Baseline and day by treatment interactions.</description>
        <time_frame>Baseline and Day 168</time_frame>
        <population>Intent-to-Treat (ITT) Population: all par. randomized to trt. who received at least one dose of randomized study drug. Par. represents those with data available at the time point being presented; however, all par. in the ITT population without missing covariate information and with at least one post BL measurement are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo QD via a DPI in the morning for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>UMEC 125 µg</title>
            <description>Participants received UMEC 125 µg QD via a DPI in the morning for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>VI 25 µg</title>
            <description>Participants received VI 25 µg QD via a DPI for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>UMEC/VI 125/25 µg</title>
            <description>Participants received UMEC/VI 125/25 µg QD via a DPI in the morning for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168</title>
          <description>FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The WM FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The WM was calculated at Days 1, 28, 84, and 168 using the 0-6-hour post-dose FEV1 measurements collected on that day, which included pre-dose (Day 1: 30 minutes [min] and 5 min prior to dosing; other serial visits: 23 and 24 hours after the previous morning dose) and post-dose at 15 min, 30 min, 1 hour, 3 hours, and 6 hours. Change from Baseline at a particular visit was calculated as the WM at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made 30 min and 5 min pre-dose on Day 1), smoking status, center group, day, and day by Baseline and day by treatment interactions.</description>
          <population>Intent-to-Treat (ITT) Population: all par. randomized to trt. who received at least one dose of randomized study drug. Par. represents those with data available at the time point being presented; however, all par. in the ITT population without missing covariate information and with at least one post BL measurement are included in the analysis.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="311"/>
                <count group_id="O3" value="298"/>
                <count group_id="O4" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.018" spread="0.0150"/>
                    <measurement group_id="O2" value="0.160" spread="0.0118"/>
                    <measurement group_id="O3" value="0.127" spread="0.0119"/>
                    <measurement group_id="O4" value="0.269" spread="0.0118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in the Mean Shortness of Breath With Daily Activities (SOBDA) Score for Week 24</title>
        <description>The newly developed SOBDA questionnaire assesses dyspnea or shortness of breath (SOB) with daily activities. The SOBDA questionnaire is made up of 13 items completed by the participant (par.) each evening prior to bedtime, when the par. is instructed to reflect on the current day’s activities. The daily score is computed as the mean of the scores on the 13 items (&gt;=7 items must have non-missing responses for this to be calculated). The par. is assigned a weekly mean SOBDA score ranging from 1 to 4 (greater scores indicate more severe breathlessness with daily activities) based on the mean of 7 days of data (&gt;=4 of 7 days must be completed for a weekly mean to be calculated). Change from BL is the mean weekly SOBDA score minus BL. Analysis was performed using MMRM with covariates of treatment, BL (mean score in the week prior to treatment), smoking status, center group, week, week by BL and week by treatment interactions. This MMRM analysis only included Weeks 4, 8, 12, and 24.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Intent-to-Treat (ITT) Population: all par. randomized to trt. who received at least one dose of randomized study drug. Par. represents those with data available at the time point being presented; however, all par. in the ITT population without missing covariate information and with at least one post BL measurement are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo QD via a DPI in the morning for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>UMEC 125 µg</title>
            <description>Participants received UMEC 125 µg QD via a DPI in the morning for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>VI 25 µg</title>
            <description>Participants received VI 25 µg QD via a DPI for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>UMEC/VI 125/25 µg</title>
            <description>Participants received UMEC/VI 125/25 µg QD via a DPI in the morning for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mean Shortness of Breath With Daily Activities (SOBDA) Score for Week 24</title>
          <description>The newly developed SOBDA questionnaire assesses dyspnea or shortness of breath (SOB) with daily activities. The SOBDA questionnaire is made up of 13 items completed by the participant (par.) each evening prior to bedtime, when the par. is instructed to reflect on the current day’s activities. The daily score is computed as the mean of the scores on the 13 items (&gt;=7 items must have non-missing responses for this to be calculated). The par. is assigned a weekly mean SOBDA score ranging from 1 to 4 (greater scores indicate more severe breathlessness with daily activities) based on the mean of 7 days of data (&gt;=4 of 7 days must be completed for a weekly mean to be calculated). Change from BL is the mean weekly SOBDA score minus BL. Analysis was performed using MMRM with covariates of treatment, BL (mean score in the week prior to treatment), smoking status, center group, week, week by BL and week by treatment interactions. This MMRM analysis only included Weeks 4, 8, 12, and 24.</description>
          <population>Intent-to-Treat (ITT) Population: all par. randomized to trt. who received at least one dose of randomized study drug. Par. represents those with data available at the time point being presented; however, all par. in the ITT population without missing covariate information and with at least one post BL measurement are included in the analysis.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="212"/>
                <count group_id="O4" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.038"/>
                    <measurement group_id="O2" value="-0.15" spread="0.029"/>
                    <measurement group_id="O3" value="-0.10" spread="0.029"/>
                    <measurement group_id="O4" value="-0.22" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until the end of treatment (up to 24 weeks).</time_frame>
      <desc>SAEs and non-serious AEs were collected in members of the ITT Population, comprised of all participants who had received at least one dose of randomized study medication during treatment period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received matching placebo QD via a DPI in the morning for 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>UMEC 125 µg</title>
          <description>Participants received UMEC 125 µg QD via a DPI in the morning for 24 weeks.</description>
        </group>
        <group group_id="E3">
          <title>VI 25 µg</title>
          <description>Participants received VI 25 µg QD via a DPI for 24 weeks.</description>
        </group>
        <group group_id="E4">
          <title>UMEC/VI 125/25 µg</title>
          <description>Participants received UMEC/VI 125/25 µg QD via a DPI in the morning for 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pancreatic atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bladder injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Starvation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Ureteric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Thromboangiitis obliterans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="113" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="102" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="407"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

